The Latest Breaking News from Vertex

Two Thirds of Preschoolers Switched to Alyftrek Reached Normal Sweat Chloride in Small Cystic Fibrosis Trial

In a 67-child open-label trial, preschoolers with cystic fibrosis who switched from Trikafta to Alyftrek saw sweat chloride fall further, with 65% reaching normal levels.

Medical Daily · Sep 14

Vertex Group expands into Singapore with SGD 8.5 million T-Ventures acquisition

It is also Vertex Group's third acquisition within a year, accelerating the company's transformation under Vertex 2.0 from a diversified business services organisation into an integrated global enterprise services and transformation platform.

The Economic Times · Aug 21

Are Wall Street Analysts Bullish on Vertex Stock?

Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.

Barchart · Aug 20

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

MarketBeat · Jun 23

Trinasolar and Ecohope Solar Sign 600MW MoU to Distribute Latest Vertex G3 Modules Across Southeast Asia, the Middle East and Africa

SHANGHAI, June 10, 2026 /PRNewswire/ -- Trinasolar, a global leader in smart PV and energy storage solutions, has signed a Memorandum of Understanding (MoU) with Ecohope Solar, a global PV and ESS solutions provider with offices in China, Thailand and the UAE. The MoU was signed at SNEC PV Power…

AAP · Jun 10

This £13k Ortofon MC Vertex is the firm's "most advanced moving coil cartridge" ever – and is joined by a new MC X model

Promises more accurate groove tracing and signal generation

What Hi-Fi? · Jun 4

Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart · Jun 1

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host

MarketBeat · May 16

MaxCyte Q1 Earnings Call Highlights

MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the declin

MarketBeat · May 13

As GitLab Expands Its Google Cloud Deal, Should You Buy GTLB Stock?

GTLB stock popped on an extended deal with Google Cloud, which is integrating with its GitLab Duo Agent Platform.

Barchart · Apr 17